A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations

Summary Acute myeloid leukaemia (AML) with FLT3 mutation has a dismal prognosis in elderly patients. Treatment with a combination of FLT3 inhibitors and standard chemotherapy has not been extensively studied. Therefore, we instigated a phase I/II clinical trial of chemotherapy with cytosine arabinos...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2015-06, Vol.169 (5), p.694-700
Hauptverfasser:	Fiedler, Walter, Kayser, Sabine, Kebenko, Maxim, Janning, Melanie, Krauter, Jürgen, Schittenhelm, Marcus, Götze, Katharina, Weber, Daniela, Göhring, Gudrun, Teleanu, Veronica, Thol, Felicitas, Heuser, Michael, Döhner, Konstanze, Ganser, Arnold, Döhner, Hartmut, Schlenk, Richard F.
Format:	Artikel
Sprache:	eng
Schlagworte:	acute myeloid leukaemia Age Factors Aged Antineoplastic Agents - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use elderly patients Female FLT3 mutation fms-Like Tyrosine Kinase 3 - genetics Humans Indoles - administration & dosage Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - mortality Male Middle Aged Mutation phase I/II study Pyrroles - administration & dosage Remission Induction sunitinib Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!